Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes

A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficiency and Safety Profile of Insulin Aspart (NovoRapid®) and Human Soluble Insulin (Novolin® R) as Meal Related Insulin in a Three Times Daily Regimen With One Injection of Novolin® N at Bedtime in Chinese Type 1 and 2 Diabetics

This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.

Inclusion Criteria:

• Type 1 or 2 diabetes for at least 4 weeks
• Treatment with oral antidiabetic drugs (OADs) and/or insulin for at least 4 weeks
• HbA1c: 7.5-13.5%
• Body Mass Index (BMI): 18-35 kg/m2

Exclusion Criteria:

• Treatment with either soluble human insulin or insulin NPH three times daily within 3 months before trial participation
• History of drug abuse or alcohol dependence